Asset profile

vorolanib · EyePoint (EYPT)

Indication: wet AMD
Also known as: DURAVYU, DURAVYU 2.7mg, vorolanib intravitreal insert, EYP-1901, DURAVYU TM

Company

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline …

Start live analysis of EYPT Run 8-agent AI analysis

On the calendar

Dec 2026

Dec 1, 2026

in 31 days

EYPTEyePoint

vorolanib: Phase 2 trial NCT06728852 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2026

Dec 31, 2026

in 61 days

EYPTEyePoint

vorolanib: Phase 2 trial NCT07386158 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Aug 2027

Aug 31, 2027

in 304 days

EYPTEyePoint

vorolanib: Phase 1/Phase 2 trial NCT06577961 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2028

Dec 30, 2028

in 791 days

EYPTEyePoint

vorolanib: Phase 3 trial NCT07165418 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Jun 2029

Jun 30, 2029

in 973 days

EYPTEyePoint

vorolanib: Phase 2 trial NCT07047001 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Oct 1, 2026

03:21 PM

EYPTEyePoint

vorolanib · NCT06523049 registry update

Trial registry changeClinicalTrials.gov Open record

Sep 10, 2026

11:05 AM

EYPTEyePoint

EYPT: LUGANO Phase 3 topline for DURAVYU in wet AMD

Topline resultsSEC 8-K Open record8 updates

Jul 30, 2026

11:00 AM

EYPTEyePoint

EyePoint completes enrollment of Phase 3 COMO and CAPRI trials for DURAVYU in DME

Trial registry changeCompany press release

Apr 13, 2026

08:05 PM

EYPTEyePoint

EyePoint: DURAVYU Phase 3 timelines updated in April 2026 investor deck

Trial registry changeSEC 8-K

Mar 2, 2026

12:05 PM

EYPTEyePoint

EyePoint starts Phase 3 COMO & CAPRI trials of DURAVYU in DME

Trial registry changeSEC 8-K

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Oct 19, 2026

Primary endpoint metConcern

EYPT: LUGANO Phase 3 topline for DURAVYU in wet AMD

Overall survival significant or trendingMixed

$118 million

US / Western patient shareFavourable

8 of 14 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

Equinox Sciences Not US-listedPartner

Betta Pharmaceuticals Not US-listedPartner

EYPTEyePointOwner

Company press release Jul 30, 2026
SEC 8-K Oct 19, 2026
SEC 8-K Oct 19, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT07047001	Phase 2	Active, not recruiting	Jun 30, 2029	60	0 of 1 sites in the United States
NCT03583086	Phase 1/2	Completed	Feb 21, 2024	88	7 of 7 sites in the United States
NCT06577961	Phase 1/2	Not yet recruiting	Aug 31, 2027	37
NCT06728852	Phase 2	Recruiting	Dec 1, 2026	32	0 of 1 sites in the United States
NCT06523049	Phase 2	Unknown	Jul 1, 2026	67	0 of 1 sites in the United States
NCT06406673	Phase 2	Unknown	Aug 30, 2024	70	0 of 1 sites in the United States
NCT07165418	Phase 3	Not yet recruiting	Dec 30, 2028	116	0 of 1 sites in the United States
NCT07386158	Phase 2	Recruiting	Dec 31, 2026	21	0 of 1 sites in the United States
NCT04373369	Phase 2	Terminated	Aug 18, 2022	11	1 of 1 sites in the United States